Generated by AI
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and immune-related diseases. Edesa Biotech’s current pipeline centers on host-directed and targeted therapies designed for medical dermatology and respiratory conditions, including investigational programs for acute respiratory distress syndrome, chronic allergic contact dermatitis, vitiligo, systemic sclerosis, and pulmonary fibrosis. The company’s work includes monoclonal antibody and topical treatment candidates intended to modulate immune pathways and address conditions with significant unmet medical needs. Edesa Biotech operates as a research and development organization, advancing its product candidates through clinical studies and related regulatory activities. Headquartered in Markham, Ontario, Canada, the company plays a specialized role in the biotechnology sector by focusing on diseases driven by dysregulated inflammatory and immune responses.
Website100 Spy Court
Markham, ON, L3R 5H6
Canada
The latest articles about EDSA.
Tipranks Press Release.
Summary of Nov 17's posts. Generated by AI.
Summary of Nov 10's posts. Generated by AI.
Summary of Mar 17's posts. Generated by AI.
Summary of Nov 11's posts. Generated by AI.
Investors talking about EDSA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.